A Study on the efficacy and safety of Docetaxel plus Nedaplatin in patients with advanced non-small-cell lung cancer
- Conditions
- non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000005031
- Lead Sponsor
- Shiga University of Medical Science
- Brief Summary
(Patients background) Enrolled patients:46 Male/Female=39/7, PS 0/1=27/19, IIIB/IV=20/27 Sq/Ad/NSCLC/AdSq=12/25/8/ Total cycles administered:144 cycles(mean:3.1 cycles) (Efficacy) CR/PR/SD/PD=0/24/11/11 Objective response rate 52.2% (24/46) (Safety) Grade 3- Leukopenia 29.2% Nausea/vomiting 3.5% Anorexia 4.2%
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1. Allergy against polysorbert 80 or platinum-containing drugs 2. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes,hemorrhagic tendency ) 3. Active infections 4. Massive pleural or pericardial effusion 5. Brain metastases with neurological symptoms. 6. Active simultaneous cancer 7. Active interstitial pneumonitis or its past history 8. Peripheral nerve disorder 9. Pregnant or lactating women 10. Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy
- Secondary Outcome Measures
Name Time Method Satety